SCHEMBL20007955

SCHEMBL20007955

CC(C)N1CCCC2(CC1)CNC(=O)O2

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.44
LMNA P02545 1/20 0.44
CHRM2 P08172 1/20 0.44
ADRA2A P08913 1/20 0.44
TSHR P16473 1/20 0.44
DRD1 P21728 1/20 0.44
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
PTPN11 Q06124 1/20 0.35
CDK8 P49336 7/20 0.35
CDK19 Q9BWU1 7/20 0.35
SMO Q99835 1/20 0.35
CCNC P24863 4/20 0.34
CYP11B2 P19099 1/20 0.34
PDCD1LG2 Q9BQ51 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
TRPV4 Q9HBA0 1/20 0.33
CHRNA7 P36544 2/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963258 0.94 CYP2D6 (0.48) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL21776108 0.88 LMNA (0.42) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL21451536 0.87 LMNA (0.41) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL29341677 0.84 CYP2D6 (0.46) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL18848901 0.80 LMNA (0.45) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL20111960 0.80 LMNA (0.50) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL25015103 0.78 LMNA (0.46) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL18896609 0.78 LMNA (0.43) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL21776132 0.77 LMNA (0.51) CYP2D6LMNACHRM2ADRA2ATSHR
SCHEMBL22770864 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515916-B1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-20200172546-A1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS, INC. 2020-06-04 US disclosed
WO-2018057884-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172546-A1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS PTPRJ, PTPN2, PTPN5 CYP2D6 3453/4885LMNA 4743/4885CHRM2 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.